Therapeutic nutraceutical treatments for osteoarthritis and ischaemia

Bibliography

• WALLACH J, LAN M: Dead doctors don't lie. Legacy Comm. Group. Franklin, TN, USA (1998).
   Google Scholar
• LAWRENCE JS, BREMMER JM, BIER F: Osteoarthrosis. Prevalence in the population and relationship between symptoms and x-ray changes. Ann. Rheum.Dis. (1966) 25:1–24.
   Google Scholar
• KELLGREN JH: Osteoarthrosis. Br. Med. J. (1961) 2:1–6.
   Google Scholar
• KELLGREN JH: Clinical trial in patients with rheuma-toid arthritis. Ann. Rheum. Dis. (1958)17:388–397.
   PubMed Web of Science ®Google Scholar
• GORDON T: Population studies of the rheumatic diseases. In Excerpta Medical Foundation, NY Bennett PH, Wood PHN (Eds.) (1968):391–397.
   Google Scholar
• EHRLICH MG, ARMSTRONG AL, TREAD WELL By, MANKINHJ: The role of proteases in the pathogenesis of osteoarthritis. j Rheumatol. (1987) 14:30–32
   PubMedGoogle Scholar
• MOSKOWITZ RD, BRANDT KD: In Arthritis and allied conditions 11th Edition, Lea, Febiger (Eds.) 1989:1605–1641.
   Google Scholar
• HOWELL DS.: Pathogenesis of osteoarthritis. Am. J. Merl. (1986) 80\(Supp1.4B):2428.
   Google Scholar
• MILLER EJ: Biochemical characteristics and biological significance of the genetically-distinct collagens. Mol. Biochem. (1976) 13:165–191.
   Google Scholar
• HEINEGARD D: Polydispersity of cartilage proteogly-cans. Structural variations with size and buoyant density of the molecules. J. Biol. Chem. (1977) 252:1980–1989.
   Google Scholar
• MAROUDAS A, EVANS H, ALMEIDA L: Cartilage of the hip joint. Topographical variation of glycosaminoglycan content in normal and fibrillated tissue. Ann. Rheum. Dis. (1973) 32:1–9.
   Google Scholar
• MANKIN HJ: The reaction of articular cartilage to injury and osteoarthritis. N Engl. J Med. (1974) 291:1285–1292.
   PubMed Web of Science ®Google Scholar
• MANKIN HJ: The reaction of articular cartilage to injury and osteoarthritis. N Engl. J. Med. (1974) 291:1335–1340.
   PubMed Web of Science ®Google Scholar
• PALMOSKI M, BRANDT K: Hyaluronate-binding by proteoglycans. Comparison of mildly and severely osteoarthritic regions of human femoral cartilage. Clin. Chem. Acta. (1976) 70:87–95.
   Google Scholar
• INEROT S, HEINEGARD D, AUDELL L, OLSSON SE: Articular-cartilage proteoglycans in aging and osteoar-thritis. Biochem. J. (1978) 169:143–156.
   PubMed Web of Science ®Google Scholar
• MANKIN HJ.: Biochemical and metabolic abnormalitiesin articular cartilage from osteoarthritic human hips. III. Distribution and metabolism of amino sugar-containing macromolecules. J. Bone Joint Surg. (1981) 63A:131–134.
   Google Scholar
• MANKIN HJ: Biochemical and metabolic abnormalitiesin articular cartilage from osteo-arthritic human hips. II. Correlation of morphology with biochemical and metabolic data. J. Bone Joint Surg. (1971) 53A:523–537.
   Google Scholar
• WEISS C.: Ultrastructural characteristics of osteoar-thritis. Fed. Proc. (1973) 12:1459–1466.
   Google Scholar
• LANE JM, WEISS C: Review of articular cartilage collagen research. Arthritis Rheum. (1975) 18:553–559.
   PubMed Web of Science ®Google Scholar
• MAROUDAS A, VENN M: Chemical composition and swelling of normal and osteoarthrotic femoral head cartilage. Ann. Rheum. Dis. (1977) 36:399–406.
   PubMed Web of Science ®Google Scholar
• DEAN DD, WOESSNER JF: Extracts of human articularcartilage contain an inhibitor of tissue metalloprote-inases. Biochem. J. (1984) 218:277–280.
   PubMedGoogle Scholar
• DEAN DD Levels of metalloproteases and tissue inhibitor of metalloproteases in human osteoarthritic cartilage. J. Rheumatol. (1987) 14(Suppl ) 43–44
   Google Scholar
• BURKHARDT H, SCHWINGEL M, MENNINGER H, MACARTNEY HW, TSCHESCHE H: Oxygen radicals as effectors of cartilage destruction. Direct degradative effect on matrix components and indirect action via activation of latent collagenase from polymorphonu-clear leukocytes. Arthritis Rheum. (1986) 29(3)379–387.
   Google Scholar
• HUSBY G, HOLME I, RUGSTAD HE, HERLAND OB, GIERCKSKY KE: A double-blind multicentre trial of piroxicam and naproxen in osteoarthritis. Clin. Rheumatol. (1986) 5:84–91.
   PubMed Web of Science ®Google Scholar
• DAVIS P: Therapeutic options in the selection ofnonsteroidal, antiinflammatory drugs in the treatment of osteoarthritis: a review. J. Rheumatol (1987) 14:94–97.
   PubMedGoogle Scholar
• BJELLE A, MJORNDAL T: Drug prescription patterns forrheumatic disorders in Sweden. J. Rheumatol (1984) 11:493–499.
   PubMedGoogle Scholar
• WILHOLM BE, MYRHED M: In Side Effects of Anti-Inflammatory Drugs Rainsford KD Velo GP (Eds.) MTD Press Ltd., Lancaster (1985):55–72.
   Google Scholar
• BUCHANAN WW, KEAN WF: Implications of antirheu-matic drug therapy in elderly patients with osteoar-thritis. j Rheumatol. (1987) 14:98–100.
   PubMedGoogle Scholar
• TAPADINHAS MJ, RIVERA IC, BIGNAMINI AA: Oral glucosamine sulfate in the management of arthrosis: report on a multi-centre open investigation in Portugal. Pharmatherapeutica (1982) 3(3):157–168.
   PubMedGoogle Scholar
• ••First glucosamine study.
   Google Scholar
• BARCLAY TS, TSOUROUNIS C, McCART GM: Glucosamine. Ann Pharmacother. (1998) 32(5)574–579.
   Google Scholar
• DE CAMARA CC, DOWLESS GV: Glucosamine sulfate forosteoarthritis. Ann. Pharmacother. (1998) 32(5)580–587.
   Google Scholar
• MCCARTY MF: The neglect of glucosamine as a treatment for osteoarthritis-a personal perspective. Med. Hypotheses (1994) 42(5):323–327.
   PubMedGoogle Scholar
• MCCARTY MF: Enhanced synovial production of hyaluronic acid may explain rapid clinical response to high-dose glucosamine in osteoarthritis. Med. Hypotheses (1998) 50(6):507–510.
   PubMedGoogle Scholar
• LEFFLER CT, PHILLIPPI AF, LEFFLER SG et al.: Glucosamine chondroitin, and manganese ascorbate for degenerative joint disease of the knee or low back: a randomized, double-blind, placebo-controlled pilot study. Mil Med. (1999) 164(2):85–91.
   PubMed Web of Science ®Google Scholar
• BUCCI RL: Chondroprotective agents glucosamine and chondroitin sulfates. Townsend Letters for Doctors (1994) 162:52–54.
   Google Scholar
• BASSLEER C, HENROTIN Y, FRANCHIMONT P: In vitro evaluation of drugs proposed as chondroprotective agents. Int. J. Tiss. Reac. (1992) 14(5):231–241.
   PubMedGoogle Scholar
• PEPITONE VR: Chondroprotection with chondroitin sulfate. Drugs Exp. Clin. Res. (1991) 17(0:3–7.
   PubMedGoogle Scholar
• ••Validates the use of chondroitin.
   Google Scholar
• TALENT JM, GRACY RW: Pilot study of oral polymeric N-acetyl-n-glucosamine as a potential treatment for patients with osteoarthritis. Clin. Ther. (1996) 6:1184–1190.
   Google Scholar
• ••Time release, economical glucosamine administration.
   Google Scholar
• TULLISON PC, TERING RL: Adenosine nucleotide synthesis in exercising and endurance-trained skeletal muscle. Am. J. Physiol (1991) 261: C342–C347.
   Google Scholar
• STATHIS CG, FEBBRAIO MA, CAREY MF, SNOW RJ: Influence of sprint training on human muscle purine nucleotide metabolism. J. Appl. Physiol. (1994) 76(4):1802–1809.
   PubMed Web of Science ®Google Scholar
• HELLSTEN-WESTING Y, BALSOM PD, NORMAN B, SJODIN B: The effect of high-intensity training on purine metabolism in man. Acta Physiol. Scand. (1993) 149:405–412.
   PubMedGoogle Scholar
• FOKER JE, EINZIG S, WANG T: Adenosine metabolism and myocardial preservation. J. Thorac. Cardiovasc. Surg. (1980) 80:506–516.
   PubMedGoogle Scholar
• ••Original ribose report
   Google Scholar
• PASQUE MK, WECHSLER A: Metabolic intervention to affect myocardial recovery following ischemia. Ann. Surg. (1984) 200:1–10.
   PubMed Web of Science ®Google Scholar
• ZIMMER HG, GERLACH E: Stimulation of myocardial adenine nucleotide biosynthesis by pentoses and pentitols. Pfluger Arch. (1978) 376:223–227.
   PubMedGoogle Scholar
• ZIMMER HG: Restitution of myocardial adenine nucleo-tides; acceleration by administration of ribose. J. Physiol. Paris (1980) 76(6):769–775.
   PubMedGoogle Scholar
• ZIMMER HG: Regulation of and intervention into the oxidative pentose phosphate pathway and adenine nucleotide metabolism of the heart. Mol. Cell. Biochem. (1996) 160/161:101–109.
   Google Scholar
• ST CYR JA, BIANCO RW, SCHNEIDER JR et al.: Enhanced high energy phosphate recovery with ribose infusion after global myocardial ischemia in a canine model. J. Surg. Res. (1989) 46:157–162.
   PubMedGoogle Scholar
• ZIMMER HG, SCHAD J: Ribose intervention in thecardiac pentose phosphate pathway is not species specific. Science (1984) 223:712–713.
   PubMedGoogle Scholar